Venetoclax Dose Escalation Triggers a Rapid BAFF–BCL-2 Survival Axis in CLL: Implications for Resistance and Combination Strategies
Highlights
– Venetoclax monotherapy rapidly reduces circulating CLL subpopulations but surviving cells upregulate prosurvival BCL-2 family proteins (BCL-2, BCL-XL, MCL-1) and show reduced drug sensitivity.
– Venetoclax treatment (and anti-CD20 therapy) is associated with an early increase in plasma BAFF levels; BAFF signaling is required for the survival-program induction in preclinical models.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.